Levetiracetam Stada

Levetiracetam, the active ingredient in Levetiracetam Stada, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset, generalized tonic‑clonic, and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to control various seizure types.

Partial‑onset seizures: reduces seizure frequency in focal epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes. Myoclonic seizures: decreases rapid, involuntary muscle jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Irritability or mood changes - Headache - Nausea or gastrointestinal discomfort

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Severe skin rash or hypersensitivity - Blood dyscrasias such as neutropenia or thrombocytopenia - Multi‑organ involvement or hepatic injury

Before initiating therapy, consider the following safety measures. - Renal impairment: adjust dose based on creatinine clearance. - Pregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional. - Psychiatric symptoms: monitor for mood swings, depression, or aggression. - Concomitant CNS depressants: may increase sedation or dizziness. - Hepatic dysfunction: use with caution and monitor liver function. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam has a relatively low interaction profile, but certain combinations require attention.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin, phenobarbital): may lower levetiracetam plasma concentrations. - Strong CYP inducers: can reduce efficacy and require dose adjustment.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Sedative hypnotics or opioids: increase risk of excessive sedation. - Other antiepileptics (e.g., valproate): may heighten adverse‑effect profile. - Renally cleared drugs: monitor renal function to avoid accumulation.